Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; however, HIV patients treated with regimens that have low cytochrome P450 (CYP450) inhibition may be allowed as long as the patient’s general health and cluster of differentiation (CD)4 counts are within acceptable levels
Patients who are known to be human immunodeficiency virus (HIV)-positive at registration are eligible at the time of registration:\r\n1. Cluster of differentiation (CD)4+ cell count greater or equal to 250 cells/mm^3\r\n2. If patient is on antiretroviral therapy, there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment; once daily combinations that use pharmacologic boosters may not be used\r\n3. No history of non-malignancy acquired immunodeficiency syndrome (AIDS)-defining conditions other than historical low CD4+ cell counts
Patients with a known history of human immunodeficiency virus (HIV) seropositivity:\r\n* Must have undetectable viral load using standard HIV assays in clinical practice\r\n* Must have cluster of differentiation (CD)4 count >= 400/mcL\r\n* Must not require prophylaxis for any opportunistic infections (i.e., fungal, Mycobacterium avium complex [mAC], or pneumocystis jiroveci pneumonia [PCP] prophylaxis)\r\n* Must not be newly diagnosed within 12 months prior to sub-study registration
Known human immunodeficiency virus (HIV)-positive patients should have a cluster of differentiation (CD)4 count > 250/mm^3
Disease must be cluster of differentiation (CD)30 positive
Patients with known human immunodeficiency virus (HIV) positive must have a cluster of differentiation (CD)4 cell count be >= 350 cells/mm^3 within 14 days prior to study entry (note, however, that HIV testing is not required for entry into this protocol)
Subjects with histopathologic confirmation of intermediate or high-grade primary central nervous system lymphoma (PCNSL) as documented by brain biopsy, or cytology (analysis from cerebral spinal fluid [CSF] or vitrectomy), and cluster of differentiation 20 (CD20) positive; whenever possible, the tumor should be characterized by immunophenotype
A stem cell product collected prior to the infusion of 153Sm-EDTMP must be available, either by peripheral stem cell mobilization or bone marrow harvest prior to trial entry; a minimum of 2 x 10^6 cluster of differentiation (CD)34+ cells/kg ideal body weight is required
Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies
A cluster of differentiation (CD)4+ lymphocyte count > 50/mcL will be required within 2 weeks of study participation
On continuous antiretrovirals with cluster of differentiation 4 (CD4) count > 200 cells/ml with sustained undetectable viral load for at least 3 months; (HIV positive women)
Prior treatment with Cluster of differentiation 33 (CD33) antibody Further exclusion criteria apply.
Histologically documented cluster of differentiation (CD) 20-positive B-cell lymphoma classified as relapsed or refractory FL or DLBCL after treatment with at least two prior chemoimmunotherapy regimens that included an anti-CD20 monoclonal antibody (mAb) and for which no other more appropriate treatment option exists
AIDS defined as a CD4 (cluster of differentiation 4) count less then 200 in the context of HIV sero-positivity or chronically is taking immunosuppressive medication such as steroids or transplant related medications.
For non-myeloablative transplants, >= 50% cluster of differentiation (CD)3 donor chimerism at screening
Cluster of differentiation (CD)4 count >= 200 within 120 days prior to enrollment or plasma HIV-1 RNA < 200 copies/mL within 120 days prior to randomization
Use of rituximab and other anti-cluster of differentiation antigen 20 (CD20) antibodies known to have the same epitope as rituximab or anti-cluster of differentiation antigen 20 (CD20) for which the epitope is unknown within 3 months prior to enrollment;
Patients must have at least 3 x 10^6 cluster of differentiation (CD)34+ cells/kg frozen
Have previously received or are ineligible for treatment with blinatumomab; ineligibility will include (but not be limited to) cluster of differentiation 19 (CD19)-negative disease, denial of insurance coverage, physician discretion, and/or patient refusal
Histologically confirmed diagnosis of cluster of differentiation (CD)30-positive ALCL with documented ALK-positive status
Cluster of differentiation (CD)4 count >= 200/uL or >= 15% of peripheral blood lymphocytes
Patients with well controlled human immunodeficiency virus (HIV) infection are eligible if their cluster of differentiation (CD)4 count is > 499/cu mm and viral load is < 50 copies/ml
Patients with known human immunodeficiency virus (HIV) infection are eligible if not on antiviral agents and cluster of differentiation (CD)4 counts are adequate (>= 500)
Availability of >= 2.5 million cluster of differentiation (CD)34+ cells/kg previously apheresed
Patient has a confirmed diagnosis of mantle cell lymphoma with B-lymphocyte antigen cluster of differentiation (CD)20 (CD20) positivity in tissue biopsy
Patients must meet the diagnostic criteria for HPS (at least 5 of the following):\r\n* Fever\r\n* Splenomegaly\r\n* Cytopenia involving >= 2 cell lines\r\n* Hypertriglyceridemia or hypofibrinogenemia\r\n* Tissue demonstration of hemophagocytosis\r\n* Hepatitis\r\n* Low or absent natural killer (NK) cell activity\r\n* Serum ferritin >= 3000 ug/L\r\n* Soluble interleukin (IL)-2 receptor (cluster of differentiation [CD25]) > 2400 U/mL
Human immunodeficiency virus (HIV) positive (+) patients with cluster of differentiation 4 (CD4) counts >= 250 cells/mm^3 on anti-viral therapy
Patients who have known human immunodeficiency virus (HIV) positivity must be on a 3-drug antiviral regimen that does not include zidovudine, and must have a cluster of differentiation (CD)4 count > 100/mm^3 and virus load < 5000 copies/ml, and are placed on a regimen to prevent pneumocystis pneumonia (PCP) reactivation during treatment
INCLUSION CRITERIA FOR ENROLLMENT: Donor cluster of differentiation (CD)3+ chimerism >= 30% measured in peripheral blood or bone marrow
Patients must have primary refractory or first relapse of cluster of differentiation 30 (CD30)+ Hodgkin lymphoma
Known sensitivity to lenalidomide or other thalidomide derivatives or anti cluster of differentiation (CD)20
Cluster of differentiation (CD)4 count >= 200/uL or >= 15% of peripheral blood lymphocytes
Relapsed/refractory MCL: Confirmed diagnosis of mantle cell lymphoma with cluster of differentiation (CD)20 and cyclin D1 through cyclin D3 positivity in tissue biopsy
Must have 4-8 x 10^6 cluster of differentiation (CD)34+ cells/kg (recipient weight) infused on day 0
Availability of autologous peripheral blood stem cell graft, containing at least 6.0 x 10^6 cluster of differentiation 34 positive (CD34+) cells/kg
A minimum of 2 x 10^6 cluster of differentiation 34 positive (CD34+) cells must have been collected
A minimum apheresis collection of 5 million cluster of differentiation (CD)34+ cells/kg of autologous hematopoietic progenitor cells (AHPC)
Patients with acquired immunodeficiency syndrome (AIDS-related illnesses) or known human immunodeficiency virus (HIV) disease must:\r\n* Have a cluster of differentiation (CD)4 count >= 200 cells/uL within 30 days before beginning study therapy\r\n* Be off all antiretroviral therapy (prophylaxis/treatment) more than 60 days before beginning study therapy, and\r\n* Have no evidence of opportunistic infections
Patients must have cluster of differentiation (CD)33 positivity of >= 30%
Cluster of differentiation 4 (CD4) count >= 200/uL
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible; unless the patient’s cluster of differentiation (CD)4+ count is below the institutional lower limit of normal
Patients with a known history of human immunodeficiency virus (HIV) seropositivity: must have undetectable viral load using standard HIV assays in clinical practice; must have cluster of differentiation (CD)4 count >= 400/mcL; must not require prophylaxis for any opportunistic infections (i.e., fungal, mycobacterium avium complex [mAC], or pneumocystis pneumonia [PCP] prophylaxis); must not be newly diagnosed within 12 months prior to re-registration
Adequate autologous stem cell collection, defined as an unmanipulated, cryopreserved, peripheral blood stem cell collection containing at least 2 x 10^6 cluster of differentiation (CD)34+ cells/kg based on patient body weight
Patients with a known history of human immunodeficiency virus (HIV) seropositivity: 1. Must have undetectable viral load using standard HIV assays in clinical practice; 2. Must have cluster of differentiation (CD)4 count >= 400/mcL; 3. Must not require prophylaxis for any opportunistic infections (i.e., fungal, mycobacterium avium complex [mAC], or pneumocystis pneumonia [PCP] prophylaxis); 4. Must not be newly diagnosed within 12 months prior to re-registration
Patients with a known history of human immunodeficiency virus (HIV) seropositivity:\r\n* Must have undetectable viral load using standard HIV assays in clinical practice\r\n* Must have cluster of differentiation (CD)4 count >= 400/mcL\r\n* Must not require prophylaxis for any opportunistic infections (i.e., fungal, mycobacterium avium complex [mAC], or pneumocystis pneumonia [PCP] prophylaxis)\r\n* Must not be newly diagnosed within 12 months prior to re-registration
Patients with any stage of pathologically confirmed cluster of differentiation (CD)3+ acute, lymphoma, chronic, or smoldering subtypes of ATLL
Subjects must be on a prophylactic regimen for Pneumocystis carinii pneumonia, or agree to begin such treatment and remain on treatment until after completion of therapy and until the cluster of differentiation (CD)4 cells are greater than 200/mm^3
Patients with known human immunodeficiency virus (HIV) are not eligible if cluster of differentiation (CD)4 count is =< 200 cell/mm^3 or if receiving antiretroviral therapy
Patients with known human immunodeficiency virus (HIV) who have cluster of differentiation (CD)4+ T cell counts >= 500 cells/mm^3 and who do not require antiretroviral therapy are eligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; if an HIV-positive patient has adequate cluster of differentiation (CD4) counts (CD4 above the lower limit of institutional normal) and is on antiretroviral therapy with newer agents, which are not strong cytochrome (CYP) inhibitors, they will be eligible
Human immunodeficiency virus (HIV)-positive patients on antiviral drugs and/or cluster of differentiation (CD)4 count is inadequate (< 500); if neither condition exists, HIV-positive patients are eligible
Patients with a history of prior treatment with ipilimumab, anti-programmed cell death 1 (PD 1) antibody, cluster of differentiation 137 (CD137) agonist or other immune activating therapy such as anti-cluster of differentiation 40 (CD 40) antibody
Cluster of differentiation (CD)4 count > 400 cells/mm^3
Lymphopenia, cluster of differentiation (CD)4 lymphopenia, leukopenia, and anemia will not render patients ineligible
Histologically documented cluster of differentiation 20 (CD20) positive lymphoma
Patients who are known to be human immunodeficiency virus (HIV) positive must have a normal cluster of differentiation (CD)4 count and undetectable viral load
Participants must have previously untreated cluster of differentiation (CD) 20-positive diffuse large, B-cell lymphoma
For obinutuzumab + Atezo + Pola treatment group: relapsed or refractory FL after treatment with at least one prior chemoimmunotherapy regimen that included an anti-Cluster of Differentiation (CD)20 monoclonal antibody and for which no other more appropriate treatment option exists as determined by the investigator
Cluster of differentiation (CD)4 count >= 200/mcL
Human immunodeficiency virus (HIV)-positive patients with inadequate cluster of differentiation (CD)4 counts or those who are on combination antiretroviral therapy with strong cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) effects are ineligible for this trial
Subjects must have measurable disease defined as at least one tumor lesion of at least 1.5 cm or a peripheral blood cluster of differentiation (CD)5+, CD19+ lymphocyte count of at least 5,000 cells/uL
Patients with a diagnosis of active human immunodeficiency virus (HIV) infection, on anti-retroviral therapy, or with a cluster of differentiation (CD) 4 count less than 200 are ineligible; testing is not required in the absence of clinical findings or suspicion
Patients with a diagnosis of active human immunodeficiency virus (HIV) infection, on anti-retroviral therapy, or with a cluster of differentiation (CD)4 count less than 200 are ineligible due to potential interactions between irinotecan and anti-retroviral medications as well as possible immunosuppressive activity of the study treatment; testing is not required in the absence of clinical findings or suspicion
Patients with human immunodeficiency virus (HIV) are eligible if they are not on antiviral agents and have adequate cluster of differentiation (CD)4 counts (>= 500 mm^3)
Human immunodeficiency virus (HIV)-positive patients with cluster of differentiation 4 (CD4) counts less than the lower limit of institutional normal
Known diagnosis of human immunodeficiency virus (HIV) infection unless patient is fully immunocompetent (cluster of differentiation 4 [CD4] > 200) and patient is not taking antiretroviral therapy
Patients must have an adequate number of cluster of differentiation (CD)34+ stem cells collected to allow for transplantation (defined as >= 2 x 10^6 CD34+ cells/kg body weight); if not previously collected and stored or if previous collection was inadequate, the patients must be willing to undergo stem cell mobilization and collection as per standard practice
Expansion Cohort: patients who have known human immunodeficiency virus (HIV) positivity must be on a 3-drug antiviral regimen that does not include zidovudine and must have a cluster of differentiation (CD4) count > 100/mm^3 and virus load < 5000 copies/mL; they must be placed on a regimen to prevent pneumocystis pneumonia (PCP) reactivation during treatment
Prior treatment with anti-cluster of differentiation (CD)20 monoclonal antibody or alemtuzumab within 2 months prior to start of therapy
Patients with HCL variant (as defined by absence of expression of cluster of differentiation [CD]25 or absence of BRAF V600E mutation)
Prior treatment with anti-cluster of differentiation (CD)20 monoclonal antibody or alemtuzumab within 3 months prior to start of therapy
Documented cluster of differentiation (CD)30+ expression from either original diagnosis or a tumor biopsy in the relapsed setting
Patients with human immunodeficiency virus (HIV) infection are eligible provided their cluster of differentiation 4 (CD4) count is greater than or equal to the institutional lower limit of normal (LLN) (>= 334 cells/uL)
Tumor cell negative for cluster of differentiation (CD)20 (absence of result due to technical problems in the presence of other characteristics suggestive of BL/DLBCL, including genetic and phenotypic features, is not an exclusion criteria)
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy will be eligible unless the cluster of differentiation (CD)4 count is < 200 cells/mm^3 within one month of study enrollment
Previous treatment with SGN-35 or any other prior anti-cluster of differentiation (CD)30-based antibody therapy
Patients with human immunodeficiency virus (HIV) disease will be permitted, only if they are on effective anti-retroviral therapy, have a cluster of differentiation (CD) 4 count greater than 400, and have had no opportunistic infections within the past 6 months
Patients must provide a lymph node sample of at least 1.5 cm in the long axis, or a bone marrow aspiration sample providing at least 5 million cluster of differentiation (CD)20 and/or CD38+ (approximately 10 ml)
History of histologically documented, B-lymphocyte antigen cluster of differentiation 20 plus (CD20+), iNHL
Patients with cluster of differentiation (CD)34 selected auto grafts
Positive for cluster of differentiation (CD)20 via immunophenotyping
Lymphoblasts may have any positive expression of cluster of differentiation (CD)20 for ofatumumab administration
Human immunodeficiency virus (HIV)-infected persons are eligible if they meet other eligibility criteria including the following:\r\n* No prior acquired immune deficiency syndrome (AIDS)-defining condition other than cluster of differentiation (CD)4+ cells nadir < 200/mm^3\r\n* Pre-leukemia CD4+ cell count >= 250/mm^3\r\n* Willing to adhere to antiretroviral therapy regimen with minimal overlapping toxicity and PK interactions with the experimental agents in this study; no zidovudine- and no ritonavir-containing regimens and no 3-drugs-in-1 pill regimens containing pharmacologic boosters are allowed; recommended regimens are integrase inhibitors combined with tenofovir and emtricitabine
Patients with cluster of differentiation (CD)20 positive diffuse large B-cell lymphoma as confirmed by a pathological biopsy report
A cluster of differentiation (CD)4+ lymphocyte count > 50/mcL will be required within 2 weeks of study participation
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible, unless the patient’s cluster of differentiation (CD)4 count is below the institutional lower limit of normal, or the patient is taking prohibited CYP3A4/5 strong inhibitors or inducers
Lymphopenia, cluster of differentiation 4 (CD4) lymphopenia, leukopenia, and anemia will not render patients ineligible
Patients must have relapsed or refractory cluster of differentiation (CD) 20+ lymphoid malignancies with either documented central nervous system (CNS) involvement or peripheral nerve infiltration
If HIV-positive, any cluster of differentiation (CD)4 count will be allowed on study
Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies
Human immunodeficiency virus (HIV)-positive patients on antiretroviral medications that are CYP3A4 substrates will be closely monitored; HIV-positive patients will be excluded if they have a cluster of differentiation 4 (CD4) count < 200
Autologous transplant eligible patients must have histologically or cytologically confirmed cluster of differentiation (CD)20 positive relapsed or refractory DLBCL by biopsy within 45 days prior to subject enrollment and must have been previously treated with an anthracycline and rituximab-containing regimen
Adequate autologous graft, defined as an unmanipulated, cryopreserved, peripheral blood stem cell graft containing at least 2 x 10^6 cluster of differentiation (CD)34+ cells/kg based on patient body weight
Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive with low cluster of differentiation (CD)4 count; Note: previous calcineurin inhibitor or previous sirolimus use allowed
If human immunodeficiency virus (HIV) positive, cluster of differentiation 4 (CD4) count must be >= 400
A cluster of differentiation (CD) 4 count > 100/mcL will be required within 2 weeks of study participation
Documented Cluster of Differentiation Antigen 20 (CD20) + B-Cell Chronic Lymphocytic Lymphoma (B-CLL)
Histopathologic confirmation of one of the following cluster of differentiation antigen 20 positive (CD20+) B-cell non-Hodgkin's lymphomas (tissue diagnostic procedures must be performed within 6 months of study entry and with biopsy material available for review):
Availability of previously collected autologous stem cells (at least 3.0 x 10^6 cluster of differentiation [CD]34 cells/kg)
Newly diagnosed cluster of differentiation (CD) 20+ DLBCL with IPI between 3-5
Patient must have cluster of differentiation (CD)34+ stem cells >= 2 x 10^6/kg (actual body weight of the recipient) available for transplantation
Human immunodeficiency virus (HIV)-positive patients who are not receiving: agents with the potential for PK interactions with romidepsin or hepatotoxic antiretrovirals (nucleoside reverse-transcriptase inhibitors [NRTIs]: abacavir, didanosine, emtricitabine, lamivudine, stavudine, and zidovudine), dual protease inhibitor (PI)-based regimens except low-dose boosting with ritonavir, atazanavir, indinavir, maraviroc, and nevirapine may be eligible; additionally, the HIV-positive patients should have a cluster of differentiation (CD)4 count > 250/mm^3; if the specific cause of hepatic dysfunction is unknown, the patient should be worked up for other viral causes of hepatitis and their eligibility determined after consultation with the principal investigator